AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33050719 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal chiropractic care + enhanced usual care (MCC+)
Number of subjects: 61
Study 33050719 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 61
Study 32416406 — intervention group
Group type: EXPERIMENTAL
Intervention: Running training intervention for 12 weeks
Number of subjects: 38
Study 32416406 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 38
Study 34569487 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 153
Study 34569487 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine-naloxone (BP-NLX)
Number of subjects: 153
Study 34569487 — intervention group
Group type: EXPERIMENTAL
Intervention: XR-NTX
Number of subjects: 153
Study 32487222 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media use disorder
Number of subjects: 456
Study 32487222 — intervention group
Group type: COMPARATOR
Intervention: Female gender
Number of subjects: 456
Study 32487222 — intervention group
Group type: COMPARATOR
Intervention: Secondary level of education
Number of subjects: 456
Study 32487222 — intervention group
Group type: COMPARATOR
Intervention: Higher social media use disorder
Number of subjects: 456
Study 32487222 — intervention group
Group type: COMPARATOR
Intervention: Higher insomnia
Number of subjects: 456
Study 32487222 — intervention group
Group type: COMPARATOR
Intervention: Higher alexithymia
Number of subjects: 456
Study 36429859 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent group-based exercise program (6-9 weeks)
Number of subjects: 200
Study 33972404 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 117
Study 33972404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 35578822 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilized hypochlorous acid solution
Number of subjects: 20
Study 35578822 — intervention group
Group type: COMPARATOR
Intervention: Control (sterile 0.9% NaCl) solution
Number of subjects: 20
Study 32141834 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable activity tracker (Fitbit Flex)
Number of subjects: 124
Study 32141834 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media (Facebook)
Number of subjects: 124
Study 32141834 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable activity trackers and social media
Number of subjects: 124
Study 35034017 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT) with adjuvant chemotherapy (AC)
Number of subjects: 139
Study 35034017 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy (CCRT) without adjuvant chemotherapy (AC)
Number of subjects: 139
Study 33942566 — intervention group
Group type: COMPARATOR
Intervention: PN-943, 100 to 1400 mg (single doses)
Number of subjects: 57
Study 33942566 — intervention group
Group type: COMPARATOR
Intervention: PN-943, 100 to 1000 mg (multiple doses)
Number of subjects: 57
Study 33942566 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg PN-943 (twice daily)
Number of subjects: 57
Study 33942566 — intervention group
Group type: COMPARATOR
Intervention: PN-943 after a high-fat meal
Number of subjects: 57
Study 33942566 — intervention group
Group type: COMPARATOR
Intervention: PN-943 (multiple doses)
Number of subjects: 57
Study 33942566 — intervention group
Group type: COMPARATOR
Intervention: PN-943 (single and multiple doses)
Number of subjects: 57
Study 32044319 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg upadacitinib twice daily
Number of subjects: 220
Study 32044319 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg upadacitinib twice daily
Number of subjects: 220
Study 32044319 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg upadacitinib twice daily
Number of subjects: 220
Study 32044319 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 mg upadacitinib twice daily
Number of subjects: 220
Study 32044319 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 mg upadacitinib once daily
Number of subjects: 220
Study 32044319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 33388813 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS over the left angular gyrus (AG)
Number of subjects: 0
Study 33388813 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the left angular gyrus (AG)
Number of subjects: 0
Study 33388813 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 32687741 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (reduced dose in elderly or low-weight group)
Number of subjects: 3997
Study 32687741 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor (standard dose)
Number of subjects: 3997
Study 32687741 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (reduced dose in neither elderly nor low-weight group)
Number of subjects: 3997
Study 35502136 — intervention group
Group type: EXPERIMENTAL
Intervention: Most positive stride width tertile
Number of subjects: 199
Study 35502136 — intervention group
Group type: EXPERIMENTAL
Intervention: Stride width of pitchers with meniscal injury
Number of subjects: 199
Study 35502136 — intervention group
Group type: COMPARATOR
Intervention: Stride width
Number of subjects: 199
Study 34267106 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 45
Study 34267106 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Interval Training (MIIT)
Number of subjects: 45
Study 34267106 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study 34267106 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT vs MIIT
Number of subjects: 45
Study 32960514 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Number of subjects: 247
Study 32960514 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine U100
Number of subjects: 247
Study 35710576 — intervention group
Group type: EXPERIMENTAL
Intervention: bDMARD tapering according to a strategy that combines disease activity guided dose optimization (DGDO) with a dynamic flare prediction model.
Number of subjects: 160
Study 35710576 — intervention group
Group type: COMPARATOR
Intervention: disease activity guided dose optimization (DGDO)
Number of subjects: 160
Study 35710576 — intervention group
Group type: EXPERIMENTAL
Intervention: bDMARD tapering according to a strategy that combines DGDO with the dynamic flare prediction model.
Number of subjects: 160
Study 33648940 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E (780 mg EGCG daily for 6 months)
Number of subjects: 39
Study 33648940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 32677772 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (diphereline) at two doses, 8 weeks before endometrial preparation
Number of subjects: 178
Study 32677772 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with estradiol valerate (6-8 mg/day)
Number of subjects: 178
Study 32677772 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (diphereline)
Number of subjects: 178
Study 36161540 — intervention group
Group type: EXPERIMENTAL
Intervention: eAsthmaCare online management
Number of subjects: 98
Study 36161540 — intervention group
Group type: COMPARATOR
Intervention: General asthma management (Control)
Number of subjects: 98
Study 33309349 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunixin meglumine (FLU) 2.2 mg/kg i.v. and whey protein placebo orally
Number of subjects: 48
Study 33309349 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam (MEL) 1 mg/kg orally and 2 mL/45 kg sterile saline placebo i.v.
Number of subjects: 48
Study 33309349 — intervention group
Group type: COMPARATOR
Intervention: Placebo (LAME + PLBO)
Number of subjects: 48
Study 33309349 — intervention group
Group type: COMPARATOR
Intervention: Placebo (SHAM + PLBO)
Number of subjects: 48
Study 33309349 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunixin meglumine (FLU)
Number of subjects: 48
Study 33309349 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam (MEL)
Number of subjects: 48
Study 34689702 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline + Rifampicin
Number of subjects: 300
Study 34689702 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline + 10% Povidone-Iodine
Number of subjects: 300
Study 34689702 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 300
Study 34689702 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidities
Number of subjects: 300
Study 34689702 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative Blood Transfusion
Number of subjects: 300
Study 34689702 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline Incision
Number of subjects: 300
Study 32285617 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP injection
Number of subjects: 90
Study 32285617 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP application
Number of subjects: 90
Study 32285617 — intervention group
Group type: COMPARATOR
Intervention: Compression therapy
Number of subjects: 90
Study 32285617 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study 34911681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg intravenously on days 1 and 15 + Tadalafil 10 mg orally once daily for 4 weeks
Number of subjects: 46
Study 34911681 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab 240 mg intravenously on days 1 and 15
Number of subjects: 46
Study 34871484 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=50)
Number of subjects: 150
Study 32985439 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative Mobile-phone Technology for Community Health Operations (ImTeCHO)
Number of subjects: 45
Study 34798846 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonidegib 200 mg once daily
Number of subjects: 66
Study 33347567 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation of 10 μg daily from age 2 weeks to 2 years
Number of subjects: 812
Study 33347567 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation of 30 μg daily from age 2 weeks to 2 years
Number of subjects: 812
Study 33347567 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of group 30 (30 μg) vs group 10 (10 μg)
Number of subjects: 812
Study 33347567 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of 25(OH)D (> 121 nmol/L)
Number of subjects: 812
Study 35239136 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic food consumption
Number of subjects: 52
Study 35239136 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 52
Study 32182633 — intervention group
Group type: EXPERIMENTAL
Intervention: RP-HPLC-MS/MS and RP-HPLC-DAD-MS methods for analysis of ecdysteroids
Number of subjects: 160
Study 32182633 — intervention group
Group type: EXPERIMENTAL
Intervention: HPLC-MS/MS with a short analysis time
Number of subjects: 160
Study 32182633 — intervention group
Group type: EXPERIMENTAL
Intervention: HPLC-MS/MS with a longer analysis time
Number of subjects: 160
Study 32182633 — intervention group
Group type: EXPERIMENTAL
Intervention: HPLC-DAD-MS
Number of subjects: 160
Study 32182633 — intervention group
Group type: EXPERIMENTAL
Intervention: Characterisation of ecdysteroids from specific species
Number of subjects: 160
Study 35322373 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF plus standard medical therapy
Number of subjects: 70
Study 35322373 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard medical therapy
Number of subjects: 70
Study 33093216 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 201
Study 33093216 — intervention group
Group type: COMPARATOR
Intervention: Placebo/nil
Number of subjects: 201
Study 34103393 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT) alone
Number of subjects: 247
Study 32474650 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 μg subcutaneous daily)
Number of subjects: 1360
Study 32474650 — intervention group
Group type: COMPARATOR
Intervention: Risedronate (35 mg oral weekly)
Number of subjects: 1360
Study 32474650 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 1360
Study 32474650 — intervention group
Group type: COMPARATOR
Intervention: Teriparatide and Risedronate
Number of subjects: 1360
Study 33739197 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Number of subjects: 40
Study 33739197 — intervention group
Group type: COMPARATOR
Intervention: Control (medical therapy alone)
Number of subjects: 40
Study 33091344 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible assertive community treatment (FACT)
Number of subjects: 2034
Study 33091344 — intervention group
Group type: COMPARATOR
Intervention: Control groups (CMHTs and ACT teams)
Number of subjects: 2034
Study 35732397 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth application for treatment support
Number of subjects: 0
Study 35732397 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 32623928 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin‐containing combination chemotherapy regimen
Number of subjects: 506
Study 32623928 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti‐Pneumocystis prophylaxis
Number of subjects: 506
Study 32623928 — intervention group
Group type: COMPARATOR
Intervention: Cumulative incidence of PCP
Number of subjects: 506
Study 32623928 — intervention group
Group type: COMPARATOR
Intervention: Mortality 30 days from PCP diagnosis
Number of subjects: 506
Study 36306029 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin cancer prevention education
Number of subjects: 0
Study 36306029 — intervention group
Group type: EXPERIMENTAL
Intervention: Education + UV photo
Number of subjects: 0
Study 36306029 — intervention group
Group type: EXPERIMENTAL
Intervention: Education + genetic testing
Number of subjects: 0
Study 36306029 — intervention group
Group type: EXPERIMENTAL
Intervention: Education + UV photo + genetic testing
Number of subjects: 0
Study 36306029 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32817271 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR)
Number of subjects: 1202
Study 32817271 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial perfusion scintigraphy (MPS)
Number of subjects: 1202
Study 32817271 — intervention group
Group type: COMPARATOR
Intervention: NICE guideline‐guided care
Number of subjects: 1202
Study 32939539 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES combined with ECC
Number of subjects: 112
Study 32939539 — intervention group
Group type: COMPARATOR
Intervention: NMES placebo combined with ECC placebo
Number of subjects: 112
Study 35705423 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher calorie refeeding
Number of subjects: 120
Study 35705423 — intervention group
Group type: COMPARATOR
Intervention: Lower calorie refeeding
Number of subjects: 120
Study 33188552 — intervention group
Group type: EXPERIMENTAL
Intervention: Bergamot phytosome (500 mg, two daily tablets)
Number of subjects: 64
Study 33188552 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two daily tablets)
Number of subjects: 64
Study 32559463 — intervention group
Group type: EXPERIMENTAL
Intervention: X‐pander®
Number of subjects: 54
Study 32559463 — intervention group
Group type: COMPARATOR
Intervention: Trial cups
Number of subjects: 54
Study 33580248 — intervention group
Group type: COMPARATOR
Intervention: SLE (−) population
Number of subjects: 1747
Study 32340817 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (LAP)
Number of subjects: 3051
Study 32340817 — intervention group
Group type: COMPARATOR
Intervention: Open surgery (OP)
Number of subjects: 3051
Study 36195936 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-slow resistance training, patient education, and a heel insert
Number of subjects: 70
Study 36195936 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency microtenotomy treatment, patient education, and a heel insert
Number of subjects: 70
Study 33940563 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine in combination with conventional cerebrovascular disease medication
Number of subjects: 165
Study 33940563 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline in combination with conventional cerebrovascular disease medication
Number of subjects: 165
Study 33940563 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram in combination with conventional cerebrovascular disease medication
Number of subjects: 165
Study 33940563 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone (Control group)
Number of subjects: 165
Study 36235553 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-reduced intervention infant formula (IF)
Number of subjects: 161
Study 36235553 — intervention group
Group type: COMPARATOR
Intervention: Control infant formula (CF)
Number of subjects: 161
Study 36235553 — intervention group
Group type: COMPARATOR
Intervention: Breastfed group (BF)
Number of subjects: 161
Study 36235553 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-1 serum concentrations at 4 months
Number of subjects: 161
Study 36235553 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin levels at 4 months
Number of subjects: 161
Study 34014689 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Assessment and Treatment Program (IATP)
Number of subjects: 198
Study 34014689 — intervention group
Group type: COMPARATOR
Intervention: Conventional motivational enhancement + cognitive-behavioral treatment (MET-CBT)
Number of subjects: 198
Study 34014689 — intervention group
Group type: EXPERIMENTAL
Intervention: IATP
Number of subjects: 198
Study 34014689 — intervention group
Group type: COMPARATOR
Intervention: MET-CBT
Number of subjects: 198
Study 32341121 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone (COMT inhibitor)
Number of subjects: 14
Study 32341121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 35501981 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified app
Number of subjects: 289
Study 35501981 — intervention group
Group type: COMPARATOR
Intervention: Nongamified app
Number of subjects: 289
Study 32862453 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient powder containing 12 mg iron for 12 weeks
Number of subjects: 22
Study 36115795 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based telerehabilitation (HBT)
Number of subjects: 45
Study 36115795 — intervention group
Group type: COMPARATOR
Intervention: In-person (IP) programs
Number of subjects: 45
Study 32681717 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete FFR-guided revascularization
Number of subjects: 110
Study 32681717 — intervention group
Group type: COMPARATOR
Intervention: Culprit-only revascularization
Number of subjects: 110
Study 32605396 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported physical activity
Number of subjects: 150
Study 32605396 — intervention group
Group type: EXPERIMENTAL
Intervention: Total physical activity
Number of subjects: 150
Study 32475261 — intervention group
Group type: EXPERIMENTAL
Intervention: ProCog‐SEP (cognitive rehabilitation program)
Number of subjects: 128
Study 32475261 — intervention group
Group type: COMPARATOR
Intervention: Placebo program (non-cognitive exercises)
Number of subjects: 128
Study 33581820 — intervention group
Group type: EXPERIMENTAL
Intervention: tE2 patches (four 100 μg patches per 24 h, changed twice weekly)
Number of subjects: 1694
Study 33581820 — intervention group
Group type: COMPARATOR
Intervention: LHRHa
Number of subjects: 1694
Study 33581820 — intervention group
Group type: EXPERIMENTAL
Intervention: tE2 patches
Number of subjects: 1694
Study 33345879 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized induction protocol (n=491)
Number of subjects: 855
Study 33345879 — intervention group
Group type: COMPARATOR
Intervention: Observational arm (n=364)
Number of subjects: 855
Study 35129210 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed respondents regarding aducanumab's potential clinical and economic impact
Number of subjects: 1025
Study 35129210 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for restricting aducanumab access
Number of subjects: 1025
Study 35129210 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to enroll family members in trials
Number of subjects: 1025
Study 35129210 — intervention group
Group type: EXPERIMENTAL
Intervention: Opinion on market withdrawal of aducanumab
Number of subjects: 1025
Study 35129210 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to pay higher premiums for coverage
Number of subjects: 1025
Study 33928797 — intervention group
Group type: EXPERIMENTAL
Intervention: GP40071 insulin aspart (GP‐Asp)
Number of subjects: 264
Study 33928797 — intervention group
Group type: COMPARATOR
Intervention: NovoRapid® (NN‐Asp)
Number of subjects: 264
Study 32697288 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy for PTSD (DBT-PTSD)
Number of subjects: 193
Study 32697288 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 193
Study 35413921 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus icatibant (30 mg subcutaneously 3 times a day for 3 days)
Number of subjects: 120
Study 35413921 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 120
Study 35413921 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus icatibant
Number of subjects: 120
Study 34156451 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-minute seated lunch condition
Number of subjects: 38
Study 34156451 — intervention group
Group type: COMPARATOR
Intervention: 10-minute seated lunch condition
Number of subjects: 38
Study 32638445 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon powder (three capsules/day each containing 600 mg of cinnamon)
Number of subjects: 50
Study 32638445 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three capsules/day each containing 100 mg of corn starch)
Number of subjects: 50
Study 33871219 — intervention group
Group type: EXPERIMENTAL
Intervention: Early lumbar disc herniation surgery within the first 6 months
Number of subjects: 67
Study 33871219 — intervention group
Group type: COMPARATOR
Intervention: Delayed lumbar disc herniation surgery after 6 months
Number of subjects: 67